Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Nyxoah's disrupting Genio implant is likely to revolutionize Obstructive Sleep Apnea, and FDA's decision is expected in Q1 ...

Shares of ResMed Inc. RMD slid 0.30% to $233.18 Friday, on what proved to be an all-around grim trading session for the stock ...

Shares of ResMed Inc. RMD inched 0.56% higher to $233.88 Thursday, on what proved to be an all-around mixed trading session ...

Shares of ResMed Inc. (NYSE:RMD – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $237.27, but opened at $230.21. ResMed shares last traded at $226 ...

Honda and Nissan begin merger talks with a plan for the combination to be completed in 2026, Qualcomm scores a victory in its licensing dispute with Arm Holdings, and the FDA approves Eli Lilly’s ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

Chip stocks advanced, led by Broadcom ( AVGO) after UBS analysts raised their price target for the stock, citing the ...

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

I have to say, this list is representative of an industry that has been through a lot.

ResMed Inc. (RMD), based in San Diego, California, is a leading provider of cloud-connected devices and digital health ...

Investment analysts at William Blair issued their Q2 2025 earnings per share estimates for shares of ResMed in a research ...